Literature DB >> 12847223

Pattern recognition by TREM-2: binding of anionic ligands.

Michael R Daws1, Paul M Sullam, Eréne C Niemi, Thomas T Chen, Nadia K Tchao, William E Seaman.   

Abstract

We recently described the cloning of murine triggering receptor expressed by myeloid cells (TREM) 2, a single Ig domain DNAX adaptor protein 12-associated receptor expressed by cells of the myeloid lineage. In this study, we describe the identification of ligands for TREM-2 on both bacteria and mammalian cells. First, by using a TREM-2A/IgG1-Fc fusion protein, we demonstrate specific binding to a number of Gram-negative and Gram-positive bacteria and to yeast. Furthermore, we show that fluorescently labeled Escherichia coli and Staphylococcus aureus bind specifically to TREM-2-transfected cells. The binding of TREM-2A/Ig fusion protein to E. coli can be inhibited by the bacterial products LPS, lipoteichoic acid, and peptidoglycan. Additionally, binding can be inhibited by a number of other anionic carbohydrate molecules, including dextran sulfate, suggesting that ligand recognition is based partly on charge. Using a sensitive reporter assay, we demonstrate activation of a TREM-2A/CD3zeta chimeric receptor by both bacteria and dextran sulfate. Finally, we demonstrate binding of TREM-2A/Ig fusion to a series of human astrocytoma lines but not to a variety of other cell lines. The binding to astrocytomas, like binding to bacteria, is inhibited by anionic bacterial products, suggesting either a similar charge-based ligand recognition method or overlapping binding sites for recognition of self- and pathogen-expressed ligands.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12847223     DOI: 10.4049/jimmunol.171.2.594

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  119 in total

Review 1.  Triggering receptor expressed on myeloid cells receptor family modulators: a patent review.

Authors:  Christopher J Pelham; Amit N Pandya; Devendra K Agrawal
Journal:  Expert Opin Ther Pat       Date:  2014-11-01       Impact factor: 6.674

Review 2.  Regulation of microglial activation in stroke.

Authors:  Shou-Cai Zhao; Ling-Song Ma; Zhao-Hu Chu; Heng Xu; Wen-Qian Wu; Fudong Liu
Journal:  Acta Pharmacol Sin       Date:  2017-03-06       Impact factor: 6.150

Review 3.  Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances.

Authors:  Gwendalyn J Randolph; Guzman Sanchez-Schmitz; Veronique Angeli
Journal:  Springer Semin Immunopathol       Date:  2005-01

Review 4.  Microglial activation in stroke: therapeutic targets.

Authors:  Midori A Yenari; Tiina M Kauppinen; Raymond A Swanson
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

5.  TREM-2, triggering receptor expressed on myeloid cell-2, negatively regulates TLR responses in dendritic cells.

Authors:  Hiroaki Ito; Jessica A Hamerman
Journal:  Eur J Immunol       Date:  2011-12-12       Impact factor: 5.532

Review 6.  The role of the microglia in acute CNS injury.

Authors:  Masahito Kawabori; Midori A Yenari
Journal:  Metab Brain Dis       Date:  2014-03-29       Impact factor: 3.584

7.  TREM-2 binds to lipooligosaccharides of Neisseria gonorrhoeae and is expressed on reproductive tract epithelial cells.

Authors:  D N Quan; M D Cooper; J L Potter; M H Roberts; H Cheng; G A Jarvis
Journal:  Mucosal Immunol       Date:  2008-03-05       Impact factor: 7.313

Review 8.  TREM and TREM-like receptors in inflammation and disease.

Authors:  Jill W Ford; Daniel W McVicar
Journal:  Curr Opin Immunol       Date:  2009-02-21       Impact factor: 7.486

9.  TREM2 governs Kupffer cell activation and explains belr1 genetic resistance to malaria liver stage infection.

Authors:  Lígia Antunes Gonçalves; Lurdes Rodrigues-Duarte; Joana Rodo; Luciana Vieira de Moraes; Isabel Marques; Carlos Penha-Gonçalves
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-11       Impact factor: 11.205

Review 10.  TREM2-Ligand Interactions in Health and Disease.

Authors:  Daniel L Kober; Tom J Brett
Journal:  J Mol Biol       Date:  2017-04-19       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.